PaulMichaelBurkatMDPhD FAPA

Psychiatry • Philadelphia, PA

Associate Professor of Clinical Psychiatry

Join to view full profile

Dr. Burkat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Burkat's full profile

Already have an account?

Office
3535 Market Street
Philadelphia, PA 19104

Education & Training

University of RochesterResidency, Psychiatry, 2006 - 2010
Penn State Milton S Hershey Medical CenterResidency, Anesthesiology, 2004 - 2004
University of Rochester School of Medicine and DentistryClass of 2003, MD
University of Rochester School of Medicine and DentistryPhD, Physiology, 1997 - 2001
University of RochesterBS, Neuroscience, Magna Cum Laude, 1991 - 1995

Certifications & Licensure

NJ State Medical License 2023 - 2025
PA State Medical License 2004 - 2024
RI State Medical License 2021 - 2022
NY State Medical License 2010 - 2015
American Board of Psychiatry and Neurology Psychiatry
American Board of Preventive Medicine Addiction Medicine

Awards, Honors, & Recognition

Fellow American Psychiatric Association
Research Colloquium for Junior Investigators Award American Psychiatric Association, 2009
Resident Research Award University of Rochester Medical Center, 2009
Junior Investigator Award University of Rochester Medical Center, 2007, 2010
Phi Beta Kappa 1995
Join now to see all

Publications & Presentations

PubMed

Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction.
Paul M Burkat
British Journal of Clinical Pharmacology. 2023-08-01
2 citations
Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling of Diazepam: Unbound Interstitial Brain Concentrations Correspond to Clinical End Points.
P M Burkat
Journal of Clinical Pharmacology. 2022-10-01
4 citations
Enhancement of α5-containing γ-aminobutyric acid type A receptors by the nonimmobilizer 1,2-dichlorohexafluorocyclobutane (F6) is abolished by the β3(N265M) mutation.
Paul M. Burkat, Chong Lor, Misha Perouansky, Robert A. Pearce
Anesthesia and Analgesia. 2014-12-01

Books/Book Chapters

Workplace Violence in the Mental and General Health Care Settings.
Chapter: Policy Development in Ambulatory Psychiatric and Chemical Dependency Services.
Page 117 - 124Burkat, P. and Baciewicz, G.Editors: Michael R. Privitera.Jones and Bartlett, Sudbury, MA2011

Committees

Member, Patient Care Improvement Committee

Professional Memberships

American Psychiatric Association - APA
Member
Pennsylvania Medical Society
Member